- Inicio
- Innovación y Tecnología
- Transferencia de Tecnología
- Ofertas de tecnología seleccionadas
Ofertas de tecnología seleccionadas
En esta sección le presentamos las últimas ofertas de tecnología incorporadas en la red EEN.
Si está interesado en un sector tecnológico determinado, pulsando el título correspondiente, obtendrá las ofertas relacionadas con dicho sector. (Pulse en un sector tecnológico determinado y encontrará todas las ofertas de dicho sector.)
Title
Technology for In-Vitro Diagnostics. The novel superfast technology for oriented and covalent immobilization.
Reference
TOES20210303001
Last update
Mon, May, 03, 2021
Deadline
Sun, May, 01, 2022
Abstract
A Spanish biotech company has developed an innovative and universal technology for site-specific conjugation of proteins.
It allows to efficiently immobilize any recombinant protein in a controlled, homogenous and convenient orientation, resulting in diagnostic tests showing higher detection sensitivity.They are seeking companies in the fields of diagnostics from the biotech or life sciences to establish Technology Evaluation Agreement, Co-development of diagnostic kits or R+D License.
Description
The technology is an innovative, universal and robust solution for site-specific conjugation of proteins.
It is based on a series of very fast and precise novel Split Inteins, superior to the so far described inteins. Inteins and Split Inteins are internal protein elements that self-excise from the precursor protein and catalyze the linkage of the two flanking sequences with a peptide bond.
Problem to solve: The most common strategy to prepare a diagnostic test is to immobilize the analyte detecting molecule on a surface by adsorption. However, this method yields different orientations of the analyte detecting molecule, some of which block, totally or partially, the recognition of the analyte, reducing the sensitivity of the assay.
Based on its specific reaction, this technology is a universal tool that allows to efficiently immobilize any recombinant protein in a controlled, homogenous and convenient orientation, resulting in diagnostic tests showing higher detection sensitivity.
Current status: Non-Exclusive Commercial License granted to a leader company in human.
How does it work?
The protein of interest is recombinantly produced in fusion to N-Int split intein. The complementary C-Int split intein is chemically synthesized or recombinantly produced, and covalently bound to a solid support through unique Cys (or other chemistries).
Due to the specific reaction between the two split-inteins, which takes place at physiological mild conditions, the protein of interest is covalently bound to the solid support. Point of binding corresponds to where the intein was placed, resulting in homogeneity and control of protein’s orientation.
The Spain SME is looking to partner with diagnostic test developers who would be interested this technology or are interested in joint development diagnostic kits with industrial partners from the biotech, pharma sector or life sciences.
Technology Keywords
Protein Engineering;Synthetic Biology;In vitro Testing, Trials
Keyword Codes:
06002004;06002006;06002007
Current Stage of Development
Intellectual Property Rights
Patents granted
IPR Comments:
Granted in EU, US, CN, KR, IL, AU, JP.
Exploitation of RTD Results
Organisation/Company Type
Organisation/Company Size
Organisation Comments
Detailed Market Application Codes (VEIC)
MA Keyword
Cellular and Molecular Biology;Enzymology/Protein Engineering/Fermentation;In vitro Testing, Trials;Micro- and Nanotechnology related to Biological sciences
MA Keyword Codes:
04006;04007;04009;04017
Application Domain Description:
Collaboration Type
Comments:
Seeking industrial partners, either Biotech or life sciences, to:
• Industry for further development and/or license via license agreement.
• Companies for collaborative and innovation projects via Technology Evaluation Agreement or Co-development.